Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority Trial of Generic Brimonidine/Timolol vs Combigan in Open Angle Glaucoma or Ocular Hypertension
2023-507285-24-00Phase 3Completed
- Sponsor
- Becro
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of brimonidine tartrate + timolol maleate in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Becro. Primary endpoint: Change in IOP at 08:00 from baseline to week 12. Started Mar 2024; status: completed.
02
Drugs
brimonidine tartrate + timolol maleate
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2023-507285-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507285-24-00.